HONG KONG – The third pre-revenue med-tech firm to list on the Hong Kong Stock Exchange in a month, New Horizon Health Technology Co. Ltd. raised HK$1.9 billion (US$245.08 million) in an IPO that began trading Thursday, Feb. 18. New Horizon placed 76.6 million shares at HK$26.66 apiece and said part of the funds will help the company commercialize its FIT-DNA test Coloclear to screen for colorectal cancer.
LONDON – Exosome specialist Evox Therapeutics Ltd. has raised $95.4 million in a series C round that will enable it to progress a number of rare disease programs into the clinic, with the lead due to enter phase I at the beginning of next year.
LONDON – Advent Life Sciences announced the close of two new transatlantic funds with a total of $215 million, to be dedicated to seed and series A funding of early stage science. The first fund is Advent’s own Life Sciences fund III, while the second is the Advent-Harrington Impact fund, which London-based Advent has raised, and will manage, on behalf of the Harrington Discovery Institute of Cleveland.
Humacyte Inc., which develops universally implantable, bioengineered human tissue at commercial scale, has agreed to go public via a merger with Alpha Healthcare Acquisition Corp. (AHAC), a blank-check company led by Rajiv Shukla. Upon closing of the deal, AHAC will be renamed Humacyte Inc. and will be led by Humacyte’s current CEO, Laura Niklason. The combined company’s stock is expected to list on the Nasdaq Capital Market under the ticker symbol HUMA.
RSS
